Agenus Inc.
NASDAQ:AGENBiotechnology
-$0.01 today
- Market cap
- $277.81M
- Beta
- 1.54
- P/E (TTM)
- 1.7
- EPS (TTM)
- $1.70
Volume 0.82M
Average 0.82M
Returns on capital
Agenus Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-0.0%
avg 100.1%
ROIC
-34.5%
avg -169.1%
ROA
0.1%
avg -64.7%
Analysis
ROA is currently the strongest return metric at 0.1% versus its period average of -64.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Garo H. Armen | Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman | USD 1.21M | 73 | 1.97M | 4.73% |
Steven J. O'Day | Chief Medical Officer | USD 902.82K | 65 | 100.00K | 0.24% |
Craig Winter | Chief Information Officer | — | — | — | — |
Kamel Djazouli | Head of Medical Affairs | — | — | — | — |
Zack Armen | Vice President of Investor Relations & Corporate Development | — | — | — | — |
Stefanie Perna-Nacar | Chief Communications & Government Relations Officer | — | — | — | — |
Tracy Mazza Clemente | Chief People Officer | — | — | — | — |
Robin G. Taylor | Chief Commercial Officer | — | — | — | — |
Todd Jude Yancey | Member of Advisory Board & Chief Strategic Advisor | — | — | — | — |
Jennifer S. Buell | Director and President & Chief Executive Officer of MiNK Therapeutics | — | 51 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 10, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +5.2% | +4.4% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +5.2% over three years. Forward estimates point to Revenue at +4.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Agenus Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about AGEN's management, answered from reported figures.
Who manages AGEN?
Agenus Inc. (AGEN) lists 10 active executives. The top listed executive is Craig Winter, Chief Information Officer.
Are AGEN insiders buying or selling?
Recent insider activity shows net buying of $37.96M.
Continue the stock analysis
Jump to another research area for this company.